Description:Merck (MRK) announced that profit more than doubled during the fourth fiscal quarter due to higher prices for its Rebif multiple sclerosis drug, as well as from cost savings from restructuring. Profit increased to 272 million Euro, or $355 million, from 133 million Euro in the same period last year.(1:33)